Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
CD206+ tumor-associated macrophages cross-present tumor antigen and drive antitumor immunity
Madhura Modak, … , Kerstin Kitt, Stefan Pflanz
Madhura Modak, … , Kerstin Kitt, Stefan Pflanz
Published May 3, 2022
Citation Information: JCI Insight. 2022;7(11):e155022. https://doi.org/10.1172/jci.insight.155022.
View: Text | PDF
Research Article Immunology Oncology

CD206+ tumor-associated macrophages cross-present tumor antigen and drive antitumor immunity

  • Text
  • PDF
Abstract

In many solid cancers, tumor-associated macrophages (TAM) represent the predominant myeloid cell population. Antigen (Ag) cross-presentation leading to tumor Ag–directed cytotoxic CD8+ T cell responses is crucial for antitumor immunity. However, the role of recruited monocyte-derived macrophages, including TAM, as potential cross-presenting cells is not well understood. Here, we show that primary human as well as mouse CD206+ macrophages are effective in functional cross-presentation of soluble self-Ag and non–self-Ag, including tumor-associated Ag (TAA), as well as viral Ag. To confirm the presence of cross-presenting TAM in vivo, we performed phenotypic and functional analysis of TAM from B16-F10 and CT26 syngeneic tumor models and have identified CD11b+F4/80hiCD206+ TAM to effectively cross-present TAA. We show that CD11b+CD206+ TAM represent the dominant tumor-infiltrating myeloid cell population, expressing a unique cell surface repertoire, promoting Ag cross-presentation and Ag-specific CD8+ T cell activation comparable with cross-presenting CLEC9A+ DCs (cDC1). The presence of cross-presenting CD206+ TAM is associated with reduced tumor burden in mouse syngeneic tumor models and with improved overall survival in cutaneous melanoma patients. Therefore, the demonstration of effective Ag cross-presentation capabilities of CD206+ TAM, including their clinical relevance, expands our understanding of TAM phenotypic diversity and functional versatility.

Authors

Madhura Modak, Ann-Kathrin Mattes, Daniela Reiss, Wioletta Skronska-Wasek, Rebecca Langlois, Nicolas Sabarth, Renate Konopitzky, Fidel Ramirez, Katharina Lehr, Tobias Mayr, David Kind, Coralie Viollet, Lee Kim Swee, Jutta Petschenka, Karim C. El Kasmi, Elfriede Noessner, Kerstin Kitt, Stefan Pflanz

×

Figure 1

CD206+ TAM are detected in human melanoma tumors and can cross-present soluble TAA in vitro.

Options: View larger image (or click on image) Download as PowerPoint
CD206+ TAM are detected in human melanoma tumors and can cross-present s...
(A) Overall survival analysis based on MRC1 expression (blue, low MRC1 TPM; red, high MRC1 TPM) in cutaneous melanoma patients (n = 229) from the TCGA database, performed using GEPIA. (B) UMAP plots showing myeloid cell populations in melanoma colored by clusters (left) and expression of MRC1 (CD206) for cell type annotation (right). (C) Bar diagram represents number of cells per indicated subsets between tumor tissue (green) and peripheral blood (violet) in melanoma patients. (B and C) The data are generated using scDVA tool. (D) Overall survival analysis based on proportion of M2 macrophage in tumor tissue (blue, low M2 macrophage proportion; red, high M2 macrophage proportion) in cutaneous melanoma patients (n = 469) from TCGA database. (A and D) Long-rank test. (E) Detection of TyrD369–377/MHC I complex with D7 TCRL antibody on in vitro–generated TAM. TAM were pretreated with TyrD short peptide (red histogram) or Scr short peptide (gray histograms). Data are representatives of 3 donors. (F) Bar diagram represents percentage of positive cells, as detected by reactivity profile of D7 antibody upon treatment of in vitro–generated TAM with short Scr peptide or TyrD peptide. (G) As in E, but cells were treated with Scr long peptide (gray histogram) or TyrD long peptide (red histogram). (H) As in F, but cells were treated with long Scr or TyrD peptide. (I and J) Bar diagrams represent IFN-γ levels in the T58/TAM coculture supernatant, where in vitro–generated TAM were pretreated with short Scr or TyrD peptide (I) and where in vitro–generated TAM were pretreated with long Scr or TyrD peptide (J). (F and H–J) Data show mean ± SEM (n = 3 donors). Unpaired Student’ t test was used. *P < 0.05, **P < 0.01.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts